Consistent with previous findings, our results demonstrated that BZYQT alleviated airway eosinophilia and hyper-responsiveness, which may be accomplished by decreasing the concentration of Th2 cytokines, eotaxin, and IgE in OVA-sensitized mice. The gene discussed is IGHE; the disease is Increased total eosinophil count.